Aligos Therapeutics, Inc. Common Stock (ALGS) is a publicly traded Healthcare sector company. As of July 7, 2026, ALGS trades at $6.57 with a market cap of $34.59M and a P/E ratio of -0.68. ALGS moved +25.76% today. Year to date, ALGS is -35.86%; over the trailing twelve months it is -25.38%. Its 52-week range spans $3.76 to $46.80. Analyst consensus is strong buy with an average price target of $72.50. Rallies surfaces ALGS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Aligos Secures $25M Upfront, $420M Milestone Deal for HBV Drug in China: Aligos received a $25M upfront payment for the exclusive Greater China license of its HBV therapy candidate pevifoscorvir sodium, which just earned Breakthrough Therapy Designation from China’s NMPA. The agreement grants potential milestones of $420M and tiered high single-digit royalties, while Aligos retains rights in other major markets.
| Metric | Value |
|---|---|
| Price | $6.57 |
| Market Cap | $34.59M |
| P/E Ratio | -0.68 |
| EPS | $-8.79 |
| Dividend Yield | 0.00% |
| 52-Week High | $46.80 |
| 52-Week Low | $3.76 |
| Volume | 70.93K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.71M |
| Net Income | $-90.32M |
| Gross Margin | 0.00% |
4 analysts cover ALGS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $72.50.